Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer

BACKGROUND: We recently showed HER2-positive breast cancers are less likely to respond to neoadjuvant anthracycline chemotherapy. Here, we investigated whether HER2-positive breast cancers responded to sequential neoadjuvant anthracycline followed by paclitaxel plus carboplatin regimen in the absenc...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Chin J Cancer Res
Egile Nagusiak: Yao, Lu, Zhang, Juan, Liu, Yiqiang, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, Xie, Yuntao
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AME Publishing Company 2015
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4697102/
https://ncbi.nlm.nih.gov/pubmed/26752929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.1000-9604.2015.12.03
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak